Investors lap up China Feihe despite declining profits and revenue
The premium infant formula maker is taking a hit from China’s low birth rate, but investors may like its dividends and transition to other dairy products Key Takeaways: China Feihe…
Recent Articles
RELATED ARTICLES
-
Butong navigates twin challenges of falling birthrates, weak consumption
-
BRIEF: Feihe buys additional 100 million yuan in wealth management products
6186.HK
-
Despite slumping revenue, Shanghai Refire cruises on government support
2570.HK
- Saint Bella births Hong Kong IPO, in race to nurture a postpartum empire
-
Yan Palace flies back to profit growth as revenue sags
1497.HK
